Skip to main content
. 2023 Feb 28;14(1):233–244. doi: 10.21037/jgo-23-6

Figure 2.

Figure 2

PUM1 enhances T-ICs expansion in CRC. (A) Real-time PCR analysis was used to ascertain the relationship between PUM1 level and CD24 (right) or EpCAM (left) in primary CRC cells (n=30). (B) Comparison of PUM1 expression in sorted CD24 (right) or EpCAM (left) primary CRC cells to negative cells using real-time PCR. (C) PUM1 expression in primary CRC adherent cells and spheres was examined using real-time PCR. (D) PUM1 expression in primary CRC adherent, sphere-like, and re-adherent cells examined using real-time PCR. (E) PUM1 expression in sorted CD24+ CRC cells as compared to negative cells as determined by real-time PCR. (F) Real-time PCR analysis PUM1 expression in sorted EpCAM+ CRC cells relative to negative cells. (G) PUM1 expression in CRC adherent cells and spheres determined using real-time PCR analysis. (H) PUM1 expression in CRC adherent, spheres and re-adherent cells determined using real-time PCR analysis. (I) PUM1 expression in cetuximab-sensitive or cetuximab-resistant CRC tissues using real-time PCR analysis. (J) Real-time PCR analysis of PUM1 in recurrent CRC and primary lesions of the patient. All results are presented as the mean ± SD, and statistical significance was assessed using a two-tailed Student’s t-test. *P<0.05. EpCAM, epithelial cell adhesion molecule; CT, cycle threshold; PUM1, pumilio homologous protein 1; mRNA, messenger RNA; CRC, colorectal cancer; T-IC, tumor-initiating cell; PCR, polymerase chain reaction; SD, standard deviation.